Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19235996 | Carbon-14 Radioisotope-Labeled Flonicamid and Synthesis Method Thereof | June 2025 | October 2025 | Allow | 4 | 1 | 0 | No | No |
| 19236398 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | June 2025 | November 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19072385 | POLQ INHIBITORS | March 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19002491 | Compounds | December 2024 | May 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 18989682 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | December 2024 | July 2025 | Allow | 7 | 2 | 0 | No | No |
| 18843302 | TRIAZOLYL CROSS-LINKING AGENT AS WELL AS PREPARATION METHOD AND USE THEREOF | September 2024 | April 2025 | Allow | 8 | 0 | 1 | Yes | No |
| 18767494 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | July 2024 | December 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18753212 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | June 2024 | July 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18718991 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18678114 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | May 2024 | March 2025 | Allow | 9 | 2 | 0 | No | No |
| 18672808 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | May 2024 | May 2025 | Allow | 12 | 0 | 1 | Yes | No |
| 18671458 | SALTS OF AN FGFR INHIBITOR | May 2024 | July 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18662345 | Crystalline Forms Of An Androgen Receptor Modulator | May 2024 | June 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18655194 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | May 2024 | November 2025 | Allow | 18 | 1 | 1 | No | No |
| 18638989 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | April 2024 | April 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18629313 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | April 2024 | May 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18602701 | PROTEIN DEGRADERS AND USES THEREOF | March 2024 | July 2025 | Allow | 16 | 1 | 0 | No | No |
| 18588051 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | February 2024 | March 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18444450 | ANALOGS OF XANOMELINE | February 2024 | June 2024 | Allow | 4 | 2 | 0 | No | No |
| 18430845 | CRYSTALLINE 4-HYDROXY-N,N-DI-N-PROPYLTRYPTAMMONIUM (4-HO-DPT) SALTS | February 2024 | August 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18425448 | 4-CYANO-1-(2-OXO-2-(SUBSTITUTED PHENYL) ETHYL) PYRIDIN-1-IUM BROMIDES AS ANTI-TUBERCULAR AGENTS | January 2024 | September 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18415359 | FLUORO BETA-CARBOLINE COMPOUNDS | January 2024 | April 2025 | Allow | 15 | 0 | 1 | Yes | No |
| 18395348 | EP2 ANTAGONIST COMPOUNDS | December 2023 | November 2024 | Allow | 11 | 1 | 1 | No | No |
| 18545545 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | December 2023 | May 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18529382 | 3-(4-METHOXYPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}-1,2,4- OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | December 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18529309 | 3-(4-METHOXYPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}-1,2,4- OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | December 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18529426 | POLQ INHIBITORS | December 2023 | February 2026 | Allow | 26 | 0 | 0 | Yes | No |
| 18515876 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | November 2023 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18513387 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | November 2023 | August 2024 | Abandon | 9 | 1 | 1 | No | No |
| 18513400 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18513418 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | November 2023 | April 2024 | Allow | 5 | 1 | 1 | No | No |
| 18388604 | NEAR-INFRARED CYANINE DYES AND CONJUGATES THEREOF | November 2023 | August 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18386724 | BENZALDEHYDE COMPOUNDS WITH DIRECT POLYMER DESTABILIZING EFFECTS TO TREAT SICKLE CELL DISEASE | November 2023 | April 2024 | Allow | 5 | 2 | 0 | Yes | No |
| 18386093 | Method For Preparing Heterocyclic Derivative Compound, Composition Containing Same Compound, And Hydrate of Same Compound | November 2023 | May 2024 | Allow | 7 | 0 | 0 | No | No |
| 18497270 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18384003 | 4-CYANO-1-(2-OXO-2-(SUBSTITUTED PHENYL) ETHYL) PYRIDIN-1-IUM BROMIDES AS ANTI-TUBERCULAR AGENTS | October 2023 | March 2025 | Abandon | 17 | 3 | 1 | No | No |
| 18490072 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18378518 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | October 2023 | January 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18377459 | THIENO[2,3-d]PYRIMIDINES AS COX-2 INHIBITORS | October 2023 | January 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18479578 | DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF | October 2023 | October 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18372856 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | September 2023 | August 2024 | Allow | 11 | 1 | 0 | No | No |
| 18368124 | CRYSTALLINE FUMARATE SALTS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | September 2023 | February 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18367645 | (6-METHYL-4-SUBSTITUTEDPHENYL-2-OXO/THIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL)(PIPERIDIN-1-YL)METHANONES AS ANTITUBERCULAR AGENTS | September 2023 | January 2024 | Allow | 4 | 2 | 0 | No | No |
| 18244276 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | September 2023 | December 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18462578 | MODULATORS OF COMPLEX I | September 2023 | April 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18240293 | KINASE INHIBITORS | August 2023 | May 2025 | Allow | 21 | 2 | 1 | Yes | No |
| 18238864 | 3-(4-METHOXYPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}-1,2,4- OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | August 2023 | January 2024 | Allow | 4 | 1 | 1 | No | No |
| 18232945 | HIGH PURITY TIN COMPOUNDS CONTAINING UNSATURATED SUBSTITUENT AND METHOD FOR PREPARATION THEREOF | August 2023 | February 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18230332 | FUSED HETEROCYCLIC MESCALINE DERIVATIVES | August 2023 | July 2025 | Allow | 23 | 4 | 1 | Yes | No |
| 18365699 | PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS THEREOF | August 2023 | November 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18262399 | FACTOR XIA INHIBITORS | July 2023 | October 2025 | Allow | 26 | 0 | 0 | Yes | No |
| 18218982 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PPAR-GAMMA INHIBITORS | July 2023 | March 2024 | Allow | 8 | 1 | 1 | No | No |
| 18218575 | POLYMORPHIC FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE | July 2023 | November 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18216975 | AZA-PODOPHYLLOTOXIN ANALOGUES AS POTENTIAL ANTI-CANCER AGENTS | June 2023 | October 2023 | Allow | 4 | 1 | 1 | Yes | No |
| 18340143 | CRYSTALLINE DIMETHYL TRYPTAMINE ANALOGUES | June 2023 | October 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18210382 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | June 2023 | January 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18267222 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | June 2023 | September 2025 | Allow | 27 | 0 | 0 | Yes | No |
| 18256094 | ANTHELMINTIC COMPOUNDS COMPRISING A PYRIDINE STRUCTURE | June 2023 | March 2026 | Allow | 33 | 1 | 1 | Yes | No |
| 18256130 | ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE | June 2023 | January 2026 | Allow | 31 | 1 | 0 | No | No |
| 18204983 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | June 2023 | November 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18254917 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | May 2023 | September 2025 | Allow | 27 | 0 | 0 | Yes | No |
| 18319774 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | May 2023 | March 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18319846 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | May 2023 | September 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18198088 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | May 2023 | November 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18197560 | Nanoprobe-Metal Chelator Complexes | May 2023 | May 2024 | Allow | 12 | 1 | 0 | No | No |
| 18315138 | DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF | May 2023 | September 2023 | Allow | 4 | 1 | 0 | No | No |
| 18312526 | PROCESS FOR PREPARING RELUGOLIX AND INTERMEDIATES THEREOF | May 2023 | December 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 18141008 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | April 2023 | March 2024 | Allow | 10 | 1 | 0 | No | No |
| 18034318 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | April 2023 | August 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18140520 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | April 2023 | March 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18303092 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | April 2023 | July 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18249704 | TERTIARY CARBOXAMIDE COMPOUNDS | April 2023 | February 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18302573 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | April 2023 | July 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18135265 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | April 2023 | November 2023 | Allow | 7 | 1 | 0 | No | No |
| 18299347 | PRODRUGS AND CONJUGATES OF DIMETHYLTRYPTAMINE | April 2023 | April 2024 | Allow | 12 | 1 | 0 | No | No |
| 18248561 | Use of 4-Nitro-3-(Trifluoromethyl)Phenol in Killing or Controlling Pomacea Canaliculata, Method for Killing or Controlling Pomacea Canaliculata, and Molluscicide | April 2023 | July 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18297569 | Compounds for Improving mRNA Splicing | April 2023 | November 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18193866 | SYNTHESIS OF N,N-DIMETHYLTRYPTAMINE-TYPE COMPOUNDS, METHODS, AND USES | March 2023 | May 2024 | Allow | 14 | 0 | 0 | Yes | No |
| 18189286 | Renewable Highly Biobased Polybenzoxazine Thermosets for Composite Applications | March 2023 | January 2024 | Allow | 10 | 1 | 0 | No | No |
| 18028213 | PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF | March 2023 | February 2026 | Allow | 35 | 1 | 1 | No | No |
| 18125095 | FURO[3,4-B]QUINOLONE COMPOUNDS AS ANTIBACTERIAL AGENTS | March 2023 | May 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18122047 | AZA-PODOPHYLLOTOXIN ANALOGUES AS POTENTIAL ANTI-CANCER AGENTS | March 2023 | September 2023 | Allow | 6 | 1 | 1 | Yes | No |
| 18116985 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PPAR-GAMMA INHIBITORS | March 2023 | October 2023 | Allow | 7 | 2 | 1 | No | No |
| 18109890 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | February 2023 | November 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18160647 | Monoacylglycerol Lipase Modulators | January 2023 | January 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18160167 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | January 2023 | July 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18097038 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | January 2023 | August 2024 | Abandon | 20 | 1 | 1 | No | No |
| 18152465 | COMPOUNDS | January 2023 | July 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18094916 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | January 2023 | May 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18069571 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | December 2022 | September 2024 | Allow | 21 | 1 | 1 | No | No |
| 18010905 | NEAR-INFRARED CYANINE DYES AND CONJUGATES THEREOF | December 2022 | August 2023 | Allow | 8 | 1 | 0 | No | No |
| 18065208 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | December 2022 | November 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 18074746 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | December 2022 | January 2024 | Allow | 13 | 1 | 0 | No | No |
| 18074163 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | December 2022 | November 2023 | Allow | 12 | 0 | 1 | No | No |
| 18071384 | SOS1 INHIBITORS | November 2022 | June 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 18057916 | METHOD FOR PREPARATION OF ASENAPINE | November 2022 | December 2023 | Allow | 13 | 1 | 1 | No | No |
| 17990979 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | November 2022 | July 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 17998870 | CRYSTALLINE 4-HYDROXY-N,N-DI-N-PROPYLTRYPTAMMONIUM (4-HO-DPT) SALTS | November 2022 | November 2023 | Allow | 12 | 1 | 1 | No | No |
| 18050557 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | October 2022 | April 2024 | Allow | 17 | 1 | 1 | No | No |
| 17997413 | CRYSTALLINE DIMETHYL TRYPTAMINE ANALOGUES | October 2022 | March 2023 | Allow | 5 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ANDERSON, REBECCA L.
With a 57.1% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner ANDERSON, REBECCA L works in Art Unit 1626 and has examined 1,787 patent applications in our dataset. With an allowance rate of 72.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner ANDERSON, REBECCA L's allowance rate of 72.4% places them in the 35% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by ANDERSON, REBECCA L receive 1.24 office actions before reaching final disposition. This places the examiner in the 16% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by ANDERSON, REBECCA L is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +17.7% benefit to allowance rate for applications examined by ANDERSON, REBECCA L. This interview benefit is in the 59% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.4% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 87.3% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 87.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 50.2% are granted (fully or in part). This grant rate is in the 49% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 17.3% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.5% of allowed cases (in the 65% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.